However, the downregulation of these proteins may also have potential side effects and affect normal cell functions; thus, further studies are needed to fully understand the mechanisms and determine the optimal strategies for downregulating P-gp and TG2 in drug-resistant breast cancer cells. This evidence concerns the gene PGP and breast carcinoma.